Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

not_yet_recruiting133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

NCT07417800
unknownnot_applicable

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

NCT04967495
unknownphase_2

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

NCT05555316

Clinical Trials (3)

Showing 3 of 3 trials
NCT07417800Not Applicable

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

Not Yet Recruiting
NCT04967495Not Applicable

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Unknown
NCT05555316Phase 2

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3